NERIDRONIC ACID FOR TREATING COMPLEX REGIONAL PAIN SYNDROME
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
1 . A method of treating allodynia associated with complex regional pain syndrome (CRPS) comprising administering neridronic acid to a human being who is suffering from allodynia associated with CRPS that is triggered by a bone fracture, wherein the method results in a reduction of the allodynia suffered by the human being.
2 . The method of claim 1 , wherein the neridronic acid is in an acid form or in an acceptable pharmaceutical salt form.
3 . The method of claim 2 , wherein the neridronic acid is in the salt form.
4 . The method of claim 3 , wherein the salt form is the disodium salt.
5 . The method of claim 2 , wherein the neridronic acid is in the acid form.
6 . The method of claim 1 , wherein the CRPS is CRPS type I.
7 . The method of claim 1 , wherein the CRPS is CRPS type II.
8 . The method of claim 1 , wherein the bone fracture is a wrist fracture.
9 . The method of claim 1 , wherein the CRPS is associated with pain that is disproportionate to the bone fracture, and the pain associated with CRPS lasts beyond a normal healing period of the bone fracture.
10 . The method of claim 9 , wherein the CRPS has spread beyond the bone fracture area to another limb or area of the body.
11 . The method of claim 1 , wherein the neridronic acid is administered orally.
12 . The method of claim 11 , wherein the neridronic acid is administered orally once daily.
13 . The method of claim 11 , wherein the neridronic acid is administered orally in an amount of about 10 mg to about 1,000 mg.
14 . The method of claim 11 , wherein the neridronic acid is administered orally in an amount of about 50 mg to about 500 mg.
15 . The method of claim 11 , wherein the neridronic acid is administered orally in an amount of about 150 mg to about 300 mg.
16 . The method of claim 11 , wherein the neridronic acid is administered orally by controlled release means.
17 . The method of claim 1 , wherein the neridronic acid is administered parenterally.
18 . The method of claim 17 , wherein the neridronic acid is administered parenterally in an amount of about 5 mg to about 500 mg.
19 . The method of claim 17 , wherein the neridronic acid is administered parenterally in an amount of about 5 mg to about 200 mg.
20 . The method of claim 17 , wherein the neridronic acid is administered parenterally in an amount of about 10 mg to about 150 mg.
21 . The method of claim 17 , wherein the human being is female.